Successful erlotinib rechallenge after gefitinib-induced acute interstitial pneumonia.
Chang
Shih-Chieh
SC
Department of Internal Medicine, National Yang-Ming University Hospital, Yilan, Taiwan.
Chang
Cheng-Yu
CY
Chen
Chiung-Yu
CY
Yu
Chong-Jen
CJ
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000069347:Erlotinib Hydrochloride; D005260:Female; D000077156:Gefitinib; D006801:Humans; D017563:Lung Diseases, Interstitial / Q000139:chemically induced* / Q000188:drug therapy; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D011799:Quinazolines / Q000008:administration & dosage; D015996:Survival Rate; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D000077156:Gefitinib